Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/34—Tobacco-abuse

Definitions

• the present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone . BACKGROUND
• Steroids including neurosteroids (e.g., allopregnanolone) are highly insoluble in aqueous solution.
• Various approaches are used to enhance aqueous dissolution, including the use of cyclodextrin solutions.
• solubility is not sufficient to permit systemic delivery for the treatment of medical conditions.
• methods of preventing, treating, reducing, and/or mitigating one or more symptoms associated with and/or caused by traumatic brain injury, Alzheimer's disease, epilepsy, anxiety, fragile X syndrome, post-traumatic stress disorder, lysosomal storage disorders (Niemann-Pick type C disease), depression (including post-partum depression), premenstrual dysphoric disorder, alcohol craving, and smoking cessation in a subject in need thereof are provided.
• the methods comprise administering to the subject a steroid.
• methods of preventing, treating, reducing, and/or mitigating symptoms associated with and/or caused by epilepsy, in a subject in need thereof comprise administering to the subject a steroid.
• the methods comprise administering to the subject a steroid.
• the steroid is a neurosteroid.
• the neurosteroid is selected from the group consisting of allopregnanolone, allotetrahydrodeoxycorticosterone, ganaxolone,
• the neurosteroid is allopregnanolone.
• the steroid is formulated in a cyclodextrin.
• the steroid is formulated in hydroxypropyl-beta- cyclodextrin or sulfobutylether-beta-cyclodextrin sodium salt.
• the subject is experiencing aura.
• the subject has been warned of an impending seizure.
• the subject is experiencing a seizure.
• the subject has status epilepticus.
• the subject has myoclonic epilepsy. In some embodiments, the subject suffers from seizure clusters. In some embodiments, the seizure is a tonic seizure. In some embodiments, the seizure is a clonic seizure. In some embodiments, the subject is a human. In some embodiments, the steroid is administered intramuscularly, intravenously or subcutaneously.
• the methods entail treating, reducing, and/or mitigating symptoms associated with and/or caused by epilepsy by intramuscularly (i.m.), subcutaneously (s.c.) or intravenously (i.v.) administering allopregnanolone formulated in a sulfobutylether-beta- cyclodextrin sodium salt.
• the epilepsy is status epilepticus.
• the steroid or neurosteroid (e.g., allopregnanolone) is administered at a dose in the range of about 0.25 mg/kg to about 15 mg/kg, e.g., about 0.25, 0.5, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15 mg/kg.
• the steroid or neurosteroid (e.g., allopregnanolone) is self-administered by the subject.
• the steroid or neurosteroid (e.g., allopregnanolone) is administered by a caregiver who is not the subject.
• compositions comprising or consisting essentially of a steroid and a cyclodextrin are provided.
• the steroid is a neurosteroid.
• the neurosteroid is selected from the group consisting of
• the steroid is allopregnanolone.
• the cyclodextrin is hydroxypropyl-beta- cyclodextrin, sulfobutylether-beta-cyclodextrin sodium salt, or mixture thereof.
• the composition comprises allopregnanolone and sulfobutylether-beta- cyclodextrin sodium salt.
• the steroid or neurosteroid e.g., allopregnanolone
• the steroid or neurosteroid (e.g. , allopregnanolone) is nebulized or aerosolized. In some embodiments, the steroid or neurosteroid (e.g., allopregnanolone) is nebulized or aerosolized without heating. In some embodiments, the nebulized or aerosolized steroid or neurosteroid (e.g., allopregnanolone) particles have a mass median aerodynamic diameter ("MMAD") of about 5 ⁇ or smaller.
• MMAD mass median aerodynamic diameter
• the nebulized or aerosolized steroid or neurosteroid (e.g., allopregnanolone) particles have a mass median aerodynamic diameter ("MMAD") of about 2-3 ⁇ .
• MMAD mass median aerodynamic diameter
• the steroid or neurosteroid (e.g., allopregnanolone) is delivered to the distal alveoli.
• administering refers to local and systemic administration, e.g., including enteral, parenteral, pulmonary, and topical/transdermal administration.
• Routes of administration for steroid or neurosteroids that find use in the methods described herein include, e.g., oral (per os (P.O.)) administration, nasal, inhalation or intrapulmonary administration, administration as a suppository, topical contact, transdermal delivery (e.g., via a transdermal patch), intrathecal (IT) administration, intravenous (“iv”) administration, intraperitoneal (“ip”) administration, intramuscular (“im”) administration, or subcutaneous (“sc”) administration, or the implantation of a slow- release device e.g., a mini-osmotic pump, a depot formulation, etc., to a subject.
• a slow- release device e.g., a mini-osmotic pump, a depot formulation, etc.
• Administration can be by any route including parenteral and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal).
• Parenteral administration includes, e.g., intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular, ionophoretic and intracranial.
• Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
• systemic administration and “systemically administered” refer to a method of administering a compound or composition to a mammal so that the compound or composition is delivered to sites in the body, including the targeted site of pharmaceutical action, via the circulatory system.
• Systemic administration includes, but is not limited to, oral, intranasal, rectal and parenteral (e.g., other than through the alimentary tract, such as intramuscular, intravenous, intra-arterial, transdermal and subcutaneous) administration.
• co-administration refers to the presence of both active agents in the blood at the same time. Active agents that are co-administered can be delivered concurrently (i.e., at the same time) or sequentially.
• the phrase "cause to be administered” refers to the actions taken by a medical professional (e.g., a physician), or a person controlling medical care of a subject, that control and/or permit the administration of the steroid or neurosteroid (e.g., allopregnanolone) to the subject.
• Causing to be administered can involve diagnosis and/or determination of an appropriate therapeutic or prophylactic regimen, and/or prescribing particular steroid or neurosteroid (e.g., allopregnanolone) for a subject.
• Such prescribing can include, for example, drafting a prescription form, annotating a medical record, and the like.
• an amount refers to the amount and/or dosage, and/or dosage regime of one or more steroid or neurosteroid (e.g., allopregnanolone) necessary to bring about the desired result e.g., an amount sufficient prevent, abort or terminate a seizure.
• steroid or neurosteroid e.g., allopregnanolone
• the terms “treating” and “treatment” refer to delaying the onset of, retarding or reversing the progress of, reducing the severity of, or alleviating or preventing either the disease or condition to which the term applies, or one or more symptoms of such disease or condition.
• the terms “reduce,” “inhibit,” “relieve,” “alleviate” refer to the detectable decrease in the frequency, severity and/or duration of seizures. A reduction in the frequency, severity and/or duration of seizures can be measured by self-assessment (e.g., by reporting of the patient) or by a trained clinical observer. Determination of a reduction of the frequency, severity and/or duration of seizures can be made by comparing patient status before and after treatment.
• mitigating refers to reduction or elimination of one or more symptoms of that pathology or disease, and/or a reduction in the rate or delay of onset or severity of one or more symptoms of that pathology or disease (e.g., seizures), and/or the prevention of that pathology or disease.
• the phrase “consisting essentially of” refers to the genera or species of active pharmaceutical agents (e.g., neurosteroid, e.g., allopregnanolone) and excipient (e.g., hydroxypropyl-beta-cyclodextrin or Captisol (sulfobutylether-beta- cyclodextrin sodium salt)) included in a method or composition.
• active pharmaceutical agents e.g., neurosteroid, e.g., allopregnanolone
• excipient e.g., hydroxypropyl-beta-cyclodextrin or Captisol (sulfobutylether-beta- cyclodextrin sodium salt) included in a method or composition.
• other unmentioned or unrecited active ingredients and inactive are expressly excluded.
• additives e.g., surfactants, acids (organic or fatty), alcohols, esters, co-solvents, solubilizers, lipids, polymers, glycols
• subject e.g., canine or feline
• laboratory mammals e.g., mouse, rat, rabbit, hamster, guinea pig
• agricultural mammals e.g., equine, bovine, porcine, ovine.
• the subject can be a human (e.g., adult male, adult female, adolescent male, adolescent female, male child, female child) under the care of a physician or other healthworker in a hospital, psychiatric care facility, as an outpatient, or other clinical context.
• a physician or other healthworker in a hospital, psychiatric care facility, as an outpatient, or other clinical context.
• the subject may not be under the care or prescription of a physician or other healthworker.
• neuroactive steroid or “neurosteroid” refers to steroid compounds that rapidly alter neuronal excitability through interaction with neurotransmitter-gated ion channels.
• Neurosteroids act as allosteric modulators of neurotransmitter receptors, such as GABA A , NMD A, and sigma receptors. Neurosteroids find use as sedatives for the purpose of general anaesthesia for carrying out surgical procedures, and in the treatment of epilepsy and traumatic brain injury.
• Illustrative neurosteroids include, e.g., allopregnanolone, Ganaxolone, alphaxolone, alphadolone, hydroxydione, minaxolone, and Althesin (a mixture of alphaxolone and alphadolone).
• Figure 1 illustrates a time course for protection by allopregnanolone (5 ⁇ ,3 ⁇ -
• Figure 2 illustrates a time course for protection by allopregnanolone (5 ⁇ ,3 ⁇ -
• FIG. 3 illustrates a time course for protection by allopregnanolone (5 ⁇ ,3 ⁇ -
• Figure 4 illustrates a time course for protection by allopregnanolone (5 ⁇ ,3 ⁇ -
• Figure 5 illustrates the effect of i.v. administration of allopregnanolone
• mice (5 ,3 - ⁇ ) (0.1-1.5 mg/kg) on the onset of myoclonic jerk, generalized clonus, and tonic extension in response to PTZ (80 mg/kg, i.p.) injection in mice. 5 ⁇ ,3 ⁇ - ⁇ was administered i.v. 1 min before PTZ injection. Bars indicate mean S.E.M. of values from eight mice, p ⁇ 0.05 compared with vehicle control group (ANOVA followed by Dunnett's test).
• Figure 6 illustrates the effect of i.v. administration of allopregnanolone
• mice (5 ⁇ ,3 ⁇ - ⁇ ) (0.1-1.5 mg/kg) on the onset of myoclonic jerk, generalized clonus, and tonic extension in response to PTZ (80 mg/kg, i.p.) injection in mice. 5 ⁇ ,3 ⁇ - ⁇ was administered i.v. 2 min before PTZ injection. Bars indicate mean S.E.M. of values from eight mice, p ⁇ 0.05 compared with vehicle control group (ANOVA followed by Dunnett's test).
• Figure 7 illustrates the effect of i.v. administration of allopregnanolone
• mice (5 ⁇ ,3 ⁇ - ⁇ ) (0.25-1.5 mg/kg) on the onset of myoclonic jerk, generalized clonus, and tonic extension in response to PTZ (80 mg/kg, i.p.) injection in mice. 5 ⁇ ,3 ⁇ - ⁇ was administered i.v. 30 min before PTZ injection. Bars indicate mean S.E.M. of values from eight mice, p ⁇ 0.05 compared with vehicle control group (ANOVA followed by Dunnett's test).
• Figure 8 illustrates the effect of i.m. administration of allopregnanolone
• mice (5 ⁇ ,3 ⁇ - ⁇ ) (0.25-1.5 mg/kg) on the onset of myoclonic jerk, generalized clonus, and tonic extension in response to PTZ (80 mg/kg, i.p.) injection in mice. 5 ⁇ ,3 ⁇ - ⁇ was administered i.m. 30 min before PTZ injection. Bars indicate mean S.E.M. of values from eight mice, p ⁇ 0.05 compared with vehicle control group (A OVA followed by Dunnett's test).
• Figure 10 illustrates a Time -concentration profile for plasma
• Treatment of status epilepicus requires rapid administration of anti-seizure agents, which are typically delivered either by the intravenous (IV) or intramuscular (IM) routes.
• Allopregnanolone (3 -hydroxy-5a-pregnan-20-one; 5 ⁇ ,3 ⁇ - ⁇ ), an endogenous progesterone-derived steroid that is a positive allosteric modulator of GABA A receptors, is a powerful anti-seizure agent with potential in the treatment of status epilepticus.
• the present study determines and demonstrates the dosing of allopregnanolone to protect against seizures when delivered intravenously (i.v.), intramuscularly (i.m.), subcutaneously (s.c.) or orally (p.o.).
• the subject has a condition that can be treated or mitigated by administration of a neurosteroid, e.g., allopregnanolone.
• Allopregnanolone has many medical uses, including the treatment, reduction, and/or mitigation of symptoms associated with and/or caused by traumatic brain injury, Alzheimer's disease, epilepsy, anxiety, fragile X syndrome, post-traumatic stress disorder, lysosomal storage disorders (Niemann-Pick type C disease), depression (including post-partum depression),
• the invention also contemplates methods of treating, reducing, and/or mitigating symptoms associated with and/or caused by traumatic brain injury, Alzheimer's disease, epilepsy, anxiety, fragile X syndrome, post-traumatic stress disorder, lysosomal storage disorders (Niemann-Pick type C disease), depression (including post- partum depression), premenstrual dysphoric disorder, alcohol craving, and smoking cessation by administration of a steroid or neurosteroid (e.g. , allopregnanolone) dissolved or suspended in a vehicle suitable for systemic administration (e.g., intramuscular, intravenous, subcutaneous), as described herein.
• a steroid or neurosteroid e.g. , allopregnanolone
• the subject has epilepsy, has a history of suffering from epileptic seizures or is suffering from epileptic seizures.
• the patient may be experiencing an electrographic or behavioral seizure or may be experiencing a seizure aura, which itself is a localized seizure that may spread and become a full blown behavioral seizure.
• the subject may be experiencing aura that alerts of the impending onset of a seizure or seizure cluster.
• the subject may be using a seizure prediction device that alerts of the impending onset of a seizure or seizure cluster.
• Implantable seizure prediction devices are known in the art and described, e.g., in D'Alessandro, et al, IEEE
• the subject may have a personal or familial history of any of the epileptic conditions described herein.
• the subject may have been diagnosed as having any of the epileptic conditions described herein.
• the subject has or is at risk of suffering a myoclonic seizure or myoclonic epilepsy, e.g., juvenile myoclonic epilepsy.
• the PTZ seizure model demonstrated herein is predictive of utility and/or activity in
• the subject may be at risk of exposure to or may have been exposed to a nerve agent or a pesticide that can cause seizures.
• nerve agents that can cause seizures include, e.g., organophosphor o us nerve agents, e.g., tabun, sarin, soman, GF, VR and/or VX.
• pesticides that can cause seizures include, e.g., organophosphate pesticides (e.g., Acephate (Orthene), Azinphos-methyl (Gusathion, Guthion), Bensulide (Betasan, Lescosan), Bomyl (Swat), Bromophos (Nexion),
• Bromophos-ethyl (Nexagan), Cadusafos (Apache, Ebufos, Rugby), Carbophenothion (Trithion), Chlorethoxyfos (Fortress), Chlorfenvinphos (Apachlor, Birlane), Chlormephos (Dotan), Chlorphoxim (Baythion-C), Chlorpyrifos (Brodan, Dursban, Lorsban),
• Chlorthiophos (Celathion), Coumaphos (Asuntol, Co-Ral), Crotoxyphos (Ciodrin, Cypona), Crufomate (Ruelene), Cyanofenphos (Surecide), Cyanophos (Cyanox), Cythioate (Cyflee, Proban), DEF (De-Green), E-Z-Off D), Demeton (Systox), Demeton-S-methyl (Duratox, Metasystoxl), Dialifor (Torak), Diazinon, Dichlorofenthion, (VC-13 Nemacide), Dichlorvos (DDVP, Vapona), Dicrotophos (Bidrin), Dimefos (Hanane, Pestox XIV), Dimethoate (Cygon, DeFend), Dioxathion (Delnav), Disulfoton (Disyston), Ditalimfos, Edifenphos, Endothion, EPBP (
• Fenamiphos Namacur
• Fenitrothion Acothion, Agrothion, Sumithion
• Fenophosphon Agritox, trichloronate
• Fensulfothion Dasanit
• Fenthion Boytex, Entex, Tiguvon
• Fonofos Dyfonate, N-2790
• Formothion Anthio
• Fosthietan Nem-A-Tak
• Heptenophos Hostaquick
• Hiometon Ekatin
• Hosalone Zaolone
• IBP Kiitazin
• Tetrachlorvinphos (Gardona, Rabon), Tetraethyl pyrophosphate (TEPP), Triazophos (Hostathion), and Trichlorfon (Dipterex, Dylox, Neguvon, Proxol).
• compositions generally comprise or consist essentially of a steroid, e.g., a neurosteroid, suspended or dissolved in vehicle appropriate for systemic administration, e.g., a cyclodextin, e.g., hydroxypropyl-beta-cyclodextrin or sulfobutylether-beta- cyclodextrin sodium salt, or mixtures thereof.
• a steroid e.g., a neurosteroid
• vehicle appropriate for systemic administration e.g., a cyclodextin, e.g., hydroxypropyl-beta-cyclodextrin or sulfobutylether-beta- cyclodextrin sodium salt, or mixtures thereof.
• a cyclodextin e.g., hydroxypropyl-beta-cyclodextrin or sulfobutylether-beta- cyclodextrin sodium
• the neurosteroid is allopregnanolone (ALP).
• Allopregnanolone also known as 3a-hydroxy-5a-pregnan-20-one or 3 ⁇ ,5 ⁇ - tetrahydroprogesterone, IUPAC name l-(3-Hydroxy-10,13-dimethyl-
• 2,3,4,5,6,7,8,9,11,12, 14, 15,16, 17-tetradecahydro-lH-cyclopenta[a]phenanthren-17- yl)ethanone and referenced as CAS number 516-54-1, is a prototypic neurosteroid present in the blood and also the brain. It is a metabolite of progesterone and modulator of GABAA receptors.
• Allopregnanolone like other GABAA receptor active neurosteroids such as allotetrahydrodeoxycorticosterone (3 a,21 -dihydroxy-5 a-pregnan-20-one; THDOC), positively modulates all GABA A receptor isoforms, those isoforms containing ⁇ -subunits exhibit greater magnitude potentiation. Allopregnanolone has pharmacological properties similar to other positive modulators of GABAA receptors, including anxiolytic and anticonvulsant activity. Allopregnanolone is neuroprotective in many animal models of neurodegenerative conditions, including, e.g., Alzheimer's disease (Wang et al., Proc Natl Acad Sci USA.
• compositions comprise a sulfate, salt, hemisuccinate, nitrosylated, derivative or congener of allopregnanolone.
• neurosteroids that can be formulated in vehicle suitable for systemic administration, include without limitation allotetrahydrodeoxycorticosterone (3a,21- dihydroxy-5a-pregnan-20-one; THDOC), 3 a,21-dihydroxy-5b-pregnan-20-one,
• pregnanolone (3a-hydroxy-5P-pregnan-20-one), Ganaxolone (INN, also known as CCD- 1042; IUPAC name (3a,5a)-3-hydroxy-5-methylpregnan-20-one; 1- [(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl- 1,2,4,5,6,7,8,9,11,12, 14, 15, 16, 17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone), alphaxolone, alphadolone, hydroxydione, minaxolone, and Althesin (a mixture of alphaxolone, alphadolone, tetrahydrodeoxycorticosterone, pregnenolone,
• DHEA dehydroepiandrosterone
• benz[e]indene-3-carbonitriles see, e.g., Hu, et al, J Med Chem. (1993) 36(24):3956-67
• 7-(2-hydroxyethyl)benz[e]indene analogues see, e.g., Han, et al., J Med Chem. (1995) 38(22):4548-56
• 3 alpha-hydroxy-5 alpha- pregnan-20-one and 3 alpha-hydroxy-5 beta-pregnan-20-one analogues see, e.g., Han, et al., J Med Chem.
• cyclopenta[b]phenanthrenes and cyclopenta[b] anthracenes see, e.g., Scaglione, et al, J Med Chem. (2008) 51(5): 1309-18); 2beta-hydroxygonane derivatives(see, e.g., Wang, et al, Tetrahedron (2007) 63(33):7977-7984); A16-alphax alone and corresponding 17- carbonitrile analogues (see, e.g., Bandyopadhyaya, et al, Bioorg Med Chem Lett.
• the steroid or neurosteroid is not a sex hormone. In various embodiments, the steroid or neurosteroid is not progesterone.
• the steroid or neurosteroid may or may not be micronized.
• the steroid or neurosteroid e.g., allopregnanolone
• the steroid or neurosteroid may or may not be enclosed in microspheres in suspension in the oil.
• the steroid and/or an analog thereof can be administered systemically, e.g., intramuscularly (IM), or depo-IM, subcutaneously (SQ), and depo-SQ), as appropriate or desired.
• the dosage form is selected to facilitate delivery to the brain (e.g., passage through the blood brain barrier).
• the steroids or neurosteroids e.g., allopregnanolone
• Dosage forms known to those of skill in the art are suitable for delivery of the steroid.
• compositions are provided that contain therapeutically effective amounts of the steroid or neurosteroid (e.g., allopregnanolone).
• the steroids or neurosteroids e.g., allopregnanolone
• suitable pharmaceutical preparations such as tablets, capsules, or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration.
• the steroids or neurosteroids e.g., steroid or neurosteroid
• steroids or neurosteroids e.g., allopregnanolone
• analogs thereof can be administered in the "native" form or, if desired, in the form of salts, esters, amides, prodrugs, derivatives, and the like, provided the salt, ester, amide, prodrug or derivative is suitable pharmacologically effective, e.g., effective in the present method(s).
• Salts, esters, amides, prodrugs and other derivatives of the active agents can be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by March (1992) Advanced Organic Chemistry; Reactions, Mechanisms and Structure, 4th Ed. N.Y. Wiley-Interscience.
• Suitable acids for preparing acid addition salts include, but are not limited to both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, orotic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
• organic acids e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tarta
• An acid addition salt can be reconverted to the free base by treatment with a suitable base.
• Certain particularly preferred acid addition salts of the active agents herein include halide salts, such as may be prepared using hydrochloric or hydrobromic acids.
• preparation of basic salts of the active agents of this invention are prepared in a similar manner using a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, or the like.
• basic salts include alkali metal salts, e.g., the sodium salt, and copper salts.
• the pKa of the counterion is preferably at least about 2 pH lower than the pKa of the drug.
• the pKa of the counterion is preferably at least about 2 pH higher than the pKa of the drug. This permits the counterion to bring the solution's pH to a level lower than the pHmax to reach the salt plateau, at which the solubility of salt prevails over the solubility of free acid or base.
• the generalized rule of difference in pKa units of the ionizable group in the active pharmaceutical ingredient (API) and in the acid or base is meant to make the proton transfer energetically favorable.
• a solid complex may form but may rapidly disproportionate (e.g. , break down into the individual entities of drug and counterion) in an aqueous environment.
• the counterion is a pharmaceutically acceptable counterion.
• Suitable anionic salt forms include, but are not limited to acetate, benzoate, benzylate, bitartrate, bromide, carbonate, chloride, citrate, edetate, edisylate, estolate, fumarate, gluceptate, gluconate, hydrobromide, hydrochloride, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl bromide, methyl sulfate, mucate, napsylate, nitrate, pamoate (embonate), phosphate and diphosphate, salicylate and disalicylate, stearate, succinate, sulfate, tartrate, tosylate, triethiodide, valerate, and the like, while suitable cationic salt forms include, but are not limited to aluminum, benzathine, calcium, ethylene diamine, lysine, magnesium, meglumine, potassium, procaine, sodium, t
• preparation of esters typically involves
• esters are typically acyl- substituted derivatives of free alcohol groups, e.g., moieties that are derived from carboxylic acids of the formula RCOOH where R is alky, and preferably is lower alkyl.
• Esters can be reconverted to the free acids, if desired, by using conventional hydrogenolysis or hydrolysis procedures.
• Amides can also be prepared using techniques known to those skilled in the art or described in the pertinent literature. For example, amides may be prepared from esters, using suitable amine reactants, or they may be prepared from an anhydride or an acid chloride by reaction with ammonia or a lower alkyl amine.
• an effective amount for administration in a single dosage is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
• an efficacious or effective amount of the steroid or neurosteroid is determined by first administering a low dose or small amount of the agent and then incrementally increasing the administered dose or dosages, adding a second or third medication as needed, until a desired effect of is observed in the treated subject with minimal or no toxic side effects.
• compositions are formulated, e.g., for oral administration, at a dose in the range of about 5 mg/kg to about 250 mg/kg of the steroid or neurosteroid ⁇ e.g.,
• allopregnanolone e.g., about 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg,
• a steroid or neurosteroid ⁇ e.g., allopregnanolone
• a physiologically acceptable vehicle carrier, excipient, binder, preservative, stabilizer, flavor, etc.
• the amount of active substance in those compositions or preparations is such that a suitable dosage in the range indicated is obtained.
• compositions are preferably formulated in a unit dosage form, each dosage containing from about 1-1000 mg, 2-800 mg, 5-500 mg, 10-400 mg, 50-200 mg, e.g., about 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg or 1000 mg of the active ingredient.
• the steroid or neurosteroid ⁇ e.g., allopregnanolone is administered systemically ⁇ e.g., intramuscularly, intravenously, subcutaneously) at a dose in the range of about 0.25 mg/kg to about 15 mg/kg, e.g., about 0.25 mg/kg to about 15 mg/kg, e.g., about 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 mg/kg.
• unit dosage from refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
• the steroids or neurosteroids ⁇ e.g., the steroids or neurosteroids
• allopregnanolone are formulated for intrapulmonary administration.
• the steroids or neurosteroids are formulated for delivery via an inhaler.
• the steroids or neurosteroids e.g., glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabramine, a, glabramine, follistatoids
• allopregnanolone are nebulized.
• Methods and systems for intrapulmonary delivery of steroids or neurosteroids e.g., allopregnanolone are known in the art and find use.
• the steroids or neurosteroids e.g., allopregnanolone
• the steroids or neurosteroids are nebulized without the input of heat.
• the size of the aerosol particulates can be within a range appropriate for intrapulmonary delivery, particularly delivery to the distal alveoli.
• the aerosol particulates have a mass median aerodynamic diameter ("MMAD") of less than about 5 ⁇ , 4 ⁇ , 3 ⁇ , for example, ranging from about 1 ⁇ to about 3 ⁇ , e.g., from about 2 ⁇ to about 3 ⁇ , e.g., ranging from about 0.01 ⁇ to about 0.10 ⁇ .
• MMAD mass median aerodynamic diameter
• Aerosols characterized by a MMAD ranging from about 1 ⁇ to about 3 ⁇ can deposit on alveoli walls through gravitational settling and can be absorbed into the systemic circulation, while aerosols characterized by a MMAD ranging from about 0.01 ⁇ to 0.10 ⁇ can also be deposited on the alveoli walls through diffusion. Aerosols characterized by a MMAD ranging from about 0.15 ⁇ to about 1 ⁇ are generally exhaled.
• aerosol particulates can have a MMAD ranging from 0.01 ⁇ to about 5 ⁇ , for example, ranging from about 0.05 ⁇ to about 3 ⁇ , for example, ranging from about 1 ⁇ to about 3 ⁇ , for example, ranging from about 0.01 ⁇ to about 0.1 ⁇ .
• the nebulized and/or aerosolized steroids or neurosteroids e.g., allopregnanolone
• the steroids or neurosteroids e.g., the steroids or neurosteroids
• allopregnanolone is formulated in a solution comprising excipients suitable for aerosolized intrapulmonary delivery.
• the solution can comprise one or more pharmaceutically acceptable carriers and/or excipients.
• Pharmaceutically acceptable refers to approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
• the solution is buffered such that the solution is in a relatively neutral pH range, for example, a pH in the range of about 4 to 8, for example, a pH in the range of about 5-7.
• the steroids or neurosteroids e.g., allopregnanolone
• a buffered solution for example, phosphate-buffered saline.
• the steroids or neurosteroids e.g., glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabra, glabramine, a, glabramine, follistatoids
• allopregnanolone is prepared as a concentrated aqueous solution.
• Ordinary metered dose liquid inhalers have poor efficiency for the delivery to the deep lung because the particle size is not sufficiently small (Kim et al., 1985 Am Rev Resp Dis 132: 137-142; and Farr et al, 1995 Thorax 50:639-644). These systems are therefore used mostly for local delivery of drugs to the pulmonary airways.
• metered doses inhalers may not be able to deliver sufficient volumes of even a concentrated steroids or neurosteroids (e.g.,
• a metered doses inhaler is not used for delivery of the steroids or neurosteroids (e.g., allopregnanolone).
• a nebulization system with the capability of delivering ⁇ 5 ⁇ particles (e.g. , the PARI LC Star, which has a high efficiency, 78% respirable fraction 0.1-5 ⁇ . see, e.g., pari.com) is used for intrapulmonary administration.
• Electronic nebulizers which employ a vibrating mesh or aperture plate to generate an aerosol with the required particle size can deliver sufficient quantities rapidly and find use (See, e.g., Knoch and Keller, 2005 Expert Opin Drug Deliv 2: 377-390). Also, custom-designed hand-held, electronic nebulizers can be made and find use.
• Aerosolized delivery of steroids or neurosteroids allows for reduced dosing to achieve desired efficacy, e.g., in comparison to intravenous or intranasal delivery. Appropriate dosing will depend on the size and health of the patient and can be readily determined by a trained clinician. Initial doses are low and then can be incrementally increased until the desired therapeutic effect is achieved with little or no adverse side effects.
• the steroids or neurosteroids e.g., allopregnanolone
• the steroids or neurosteroids are administered via the intrapulmonary route at a dose in the range of about 0.05 mg/kg to about 1.0 mg/kg, for example, about 0.2 mg/kg to about 0.8 mg/kg, for example, about 0.05 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg, 0.9 mg/kg, or 1.0 mg/kg.
• the steroids or neurosteroids are administered via the intrapulmonary route at a dose in the range of about 0.05 mg/kg to about 1.0 mg/kg, for example, about 0.2 mg/kg to about 0.8 mg/kg, for example, about 0.05 mg/kg, 0.08 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg, 0.9 mg/kg, or
• a dose in the range of about 10 ⁇ g/kg to about 80 ⁇ /kg for example, about 20 ⁇ /kg to about 60 ⁇ g/kg, for example, about 25 ⁇ g/kg to about 50 ⁇ g/kg, for example, about 10 ⁇ g/kg, 15 ⁇ g/kg, 20 ⁇ g/kg, 25 ⁇ /kg, 30 ⁇ g/kg, 35 ⁇ , 40 ⁇ g/kg, 45 ⁇ g/kg, 50 ⁇ /kg, 60 ⁇ /kg, 70 ⁇ g/kg, or 80 ⁇ g/kg.
• a dose in the range of about 10 ⁇ g/kg to about 80 ⁇ /kg for example, about 20 ⁇ /kg to about 60 ⁇ g/kg, for example, about 25 ⁇ g/kg to about 50 ⁇ g/kg, for example, about 10 ⁇ g/kg, 15 ⁇ g/kg, 20 ⁇ g/kg, 25 ⁇ /kg, 30 ⁇ g/kg, 35 ⁇ , 40 ⁇ g/kg, 45
• the steroids or neurosteroids are administered via the intrapulmonary route at a dose in the range of about 0.3 ⁇ g/kg to about 3.0 ⁇ g/kg.
• compositions the steroid or neurosteroid (e.g., allopregnanolone) is mixed with a suitable pharmaceutically acceptable carrier.
• a suitable pharmaceutically acceptable carrier e.g., a pharmaceutically acceptable carrier.
• the resulting mixture may be a solution, suspension, emulsion, or the like.
• Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art.
• the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the steroid or neurosteroid (e.g. , allopregnanolone) in the selected carrier or vehicle.
• the effective concentration is sufficient for lessening or ameliorating at least one symptom of the disease, disorder, or condition treated and may be empirically determined.
• Pharmaceutical carriers or vehicles suitable for administration of the steroids or neurosteroids include any such carriers known to those skilled in the art to be suitable for the particular mode of administration (e.g. , cyclodextrins).
• the active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, or have another action.
• the steroids or neurosteroids e.g. , allopregnanolone
• steroids or neurosteroids e.g., allopregnanolone
• methods for solubilizing include, but are not limited to, using cosolvents such as dimethylsulfoxide (DMSO), using surfactants such as TweenTM, and dissolution in aqueous sodium bicarbonate.
• cosolvents such as dimethylsulfoxide (DMSO)
• surfactants such as TweenTM
• dissolution in aqueous sodium bicarbonate e.g., allopregnanolone
• salts or prodrugs may also be used in formulating effective pharmaceutical compositions.
• the concentration of the steroid or neurosteroid is effective for delivery of an amount upon administration that lessens or ameliorates at least one symptom of the disorder for which the compound is administered and/or that is effective in a prophylactic context.
• the compositions are formulated for single dosage (e.g. , daily) administration.
• the steroids or neurosteroids may be prepared with carriers that protect them against rapid elimination from the body, such as time-release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems.
• the active steroid or neurosteroid e.g., allopregnanolone
• the therapeutically effective concentration may be determined empirically by testing the steroids or neurosteroids (e.g., allopregnanolone) in known in vitro and in vivo model systems for the treated disorder.
• prophylactically effective dose can be determined by first administering a low dose, and then incrementally increasing until a dose is reached that achieves the desired effect with minimal or no undesired side effects.
• the steroids or neurosteroids e.g., the steroids or neurosteroids
• kits for example, including component parts that can be assembled for use.
• a compound inhibitor in lyophilized form and a suitable diluent may be provided as separated components for combination prior to use.
• a kit may include a compound inhibitor and a second therapeutic agent for co-administration.
• the inhibitor and second therapeutic agent may be provided as separate component parts.
• a kit may include a plurality of containers, each container holding one or more unit dose of the compounds.
• the containers are preferably adapted for the desired mode of administration, including, but not limited to depot products, pre-filled syringes, ampules, vials, and the like for parenteral administration
• the concentration and/or amount of steroid or neurosteroid e.g. ,
• allopregnanolone in the drug composition will depend on absorption, inactivation, and excretion rates of the steroid or neurosteroid (e.g. , allopregnanolone), the dosage schedule, and amount administered as well as other factors known to those of skill in the art.
• the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated.
• administration of a steroid or neurosteroid ⁇ e.g., allopregnanolone to a subject results in the prevention or mitigation of one or more symptoms of the disease condition being treated ⁇ e.g., traumatic brain injury, Alzheimer's disease, epilepsy, anxiety, fragile X syndrome, post-traumatic stress disorder, lysosomal storage disorders (Niemann-Pick type C disease), depression (including post-partum depression), premenstrual dysphoric disorder, alcohol craving, and smoking cessation).
• symptoms of the disease condition being treated e.g., traumatic brain injury, Alzheimer's disease, epilepsy, anxiety, fragile X syndrome, post-traumatic stress disorder, lysosomal storage disorders (Niemann-Pick type C disease), depression (including post-partum depression), premenstrual dysphoric disorder, alcohol craving, and smoking cessation).
• Symptoms of disease can be compared before and after administration of a steroid or neurosteroid ⁇ e.g., allopregnan
• Administration of the steroid or neurosteroid ⁇ e.g., allopregnanolone) to the subject is considered to be effective if the symptoms no longer occur after administration ⁇ e.g., seizures), or if the symptoms are reduced, alleviated and/or mitigated after administration.
• administration of a steroid or neurosteroid ⁇ e.g., allopregnanolone) to a subject results in the prevention of the occurrence of an impending seizure and/or the termination or abortion of a seizure in progress.
• efficacy can be monitored by the subject.
• the subject in a subject experiencing aura or receiving a warning from a seizure prediction device, the subject can self-administer a dose of the steroid or neurosteroid ⁇ e.g. , allopregnanolone). If the steroid or neurosteroid ⁇ e.g., allopregnanolone) is administered in an efficacious amount, the sensation of aura should subside and/or the seizure prediction device should no longer predict the imminent occurrence of an impending seizure.
• a second dose of steroid or neurosteroid ⁇ e.g., allopregnanolone can be administered.
• the efficacy is monitored by a caregiver. For example, in a subject experiencing the onset of a seizure or in situations where a seizure has commenced, the subject may require administration of the steroid or neurosteroid (e.g., allopregnanolone) by a caregiver. If the steroid or neurosteroid (e.g.
• allopregnanolone is administered in an efficacious amount, the seizure, along with the subject's symptoms of the seizure, should terminate or abort. If the seizure does not terminate, a second dose of the steroid or neurosteroid (e.g. , allopregnanolone) can be administered.
• the steroid or neurosteroid e.g. , allopregnanolone
• Treatment of status epilepicus requires rapid administration of antiseizure agents, which are typically delivered either by the intravenous (i.v.) or intramuscular (i.m.) routes.
• Allopregnanolone (3 -hydroxy-5a-pregnan-20-one; 5 ⁇ ,3 ⁇ - ⁇ ), an endogenous progesterone-derived steroid that is a positive allosteric modulator of GABA A receptors, is a powerful antiseizure agent with potential in the treatment of status epilepticus.
• the objective of this study was to determine the dosing of allopregnanolone to protect against seizures when delivered i.v. and i.m.
• Anticonvulsant activity was assessed by the delay in onset of seizure signs. Allopregnanolone plasma levels in rats were determined by LC-MS. RESULTS: [0076] 5 ⁇ ,3 ⁇ - ⁇ exhibited protective activity in the 6 Hz test 1-15 min after i.v. infusion (1.5 mg/kg) but was inactive at 30 min. In contrast, with i.m. administration (3 mg/kg) the onset of protective activity was slower (within 2 min) and lasted ⁇ 2 h. At a dose of 0.1 mg/kg i.v.
• 5 ⁇ ,3 ⁇ - ⁇ failed to significantly delay seizure onset in the PTZ model at all pretreatment times (1, 2 and 30 min) whereas a dose of 0.5 mg/kg administered 1 min before PTZ caused a marked delay for myoclonic jerks and clonic seizures and in 62.5% of animals prevented tonic seizures and mortality that invariably accompanies tonic seizures.
• a dose of 0.5 mg/kg administered 1 min before PTZ caused a marked delay for myoclonic jerks and clonic seizures and in 62.5% of animals prevented tonic seizures and mortality that invariably accompanies tonic seizures.
• 2 min before PTZ 5 ⁇ ,3 ⁇ - ⁇ (0.5 mg/kg) caused a similar increase in time to onset of seizures signs and prevented tonic seizures in 25% of animals.
• 5 ⁇ ,3 ⁇ - ⁇ at a dose of 1.5 mg/kg completely prevented tonic seizures and mortality when injected i.v. 1 and 2 min before PTZ.
• 5 -pregnan-20-one; 5 ⁇ ,3 ⁇ - ⁇ ) was synthesized by a SAFC Pharma Inc, Madison, WI, USA and Captisol (sulfobutylether-beta-cyclodextrin sodium salt) was provided by Ligand Pharmaceuticals, Inc. La Jolla, CA, USA. Solutions of 5 ⁇ ,3 ⁇ - ⁇ were made in 6% (0.5 and 1.5 mg/ml) or 24% (6 mg/kg) sulfobutylether-P-cyclodextrin sodium salt (Captisol®) in
• 5 ⁇ ,3 ⁇ - ⁇ (0.5 - 6 mg/kg) was administered intravenously (i.v.), intramuscularly (i.m.), subcutaneously (s.c.) or orally (p.o.) before electrical stimulation.
• 5 ⁇ ,3 ⁇ - ⁇ or vehicle were administered i.v. or i.m. 1, 2 or 30 min before PTZ.
• Seizures models [0081] 6-Hz seizure test (Kaminski, et al., Epilepsia (2004) 45 : 1-4): 3-s corneal stimulation (200- ⁇ 8 duration, 32-mA monopolar rectangular pulses at 6 Hz) was delivered by a constant-current device (ECT Unit 5780; Ugo Basile, Comerio, Italy). After the stimulation, the animals exhibited a "stunned" posture associated with rearing and automatic movements that lasted from 60 to 120 s in untreated animals. The experimental end point was protection against the seizure: an animal was considered to be protected if it resumed its normal exploratory behavior within 10 s of stimulation.
• mice were injected intraperitoneally with PTZ (80 mg/kg) and were observed for a 30-min period. The time of onset of myoclonic jerks, clonus and tonic extension was recorded.
• Results are shown in Figures 1-10.
• Our results demonstrate that i.v. 5 ⁇ ,3 ⁇ - ⁇ provides very rapid but transitory anticonvulsant activity.
• 5 ⁇ ,3 ⁇ - ⁇ acts comparably quickly and has a longer duration of action.
• Low bioavailability of 5 ⁇ ,3 ⁇ - ⁇ after oral administration prolongs the time of the peak effect and duration of action.
• Parenteral 5 ⁇ ,3 ⁇ - ⁇ is useful for the acute treatment of seizures.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Psychiatry (AREA)
• Addiction (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Pain & Pain Management (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=50828483

Family Applications (1)

Country Status (8)

Cited By (30)

Families Citing this family (5)

Citations (21)

Family Cites Families (65)

• 2013
  • 2013-11-27 JP JP2015545458A patent/JP2016501876A/ja not_active Withdrawn
  • 2013-11-27 ES ES13857993T patent/ES2973320T3/es active Active
  • 2013-11-27 DK DK13857993.3T patent/DK2925327T3/da active
  • 2013-11-27 WO PCT/US2013/072351 patent/WO2014085668A1/en not_active Ceased
  • 2013-11-27 EP EP23211768.9A patent/EP4335505A3/en active Pending
  • 2013-11-27 US US14/646,886 patent/US20150313915A1/en not_active Abandoned
  • 2013-11-27 EP EP13857993.3A patent/EP2925327B1/en active Active
  • 2013-11-27 AU AU2013352141A patent/AU2013352141B2/en active Active
  • 2013-11-27 CA CA2892811A patent/CA2892811A1/en active Pending
• 2017
  • 2017-06-25 US US15/632,360 patent/US20180133229A1/en not_active Abandoned
• 2018
  • 2018-03-09 US US15/917,245 patent/US10251894B2/en active Active
  • 2018-07-04 AU AU2018204865A patent/AU2018204865B2/en active Active
  • 2018-07-11 JP JP2018131186A patent/JP6966981B2/ja active Active
• 2019
  • 2019-01-07 US US16/241,877 patent/US20190142845A1/en not_active Abandoned
• 2020
  • 2020-03-17 AU AU2020201919A patent/AU2020201919B2/en active Active
  • 2020-10-06 US US17/064,517 patent/US20210100817A1/en not_active Abandoned
• 2021
  • 2021-06-30 JP JP2021108255A patent/JP7744166B2/ja active Active
• 2022
  • 2022-05-03 AU AU2022202943A patent/AU2022202943B2/en active Active
• 2023
  • 2023-08-02 JP JP2023125962A patent/JP2023133494A/ja active Pending
• 2024
  • 2024-02-14 US US18/442,086 patent/US20240197754A1/en active Pending

Patent Citations (22)

Non-Patent Citations (33)

Also Published As

Similar Documents

Legal Events